No Data
No Data
Express News | Akoya Biosciences Inc : Stephens Cuts Target Price to $4.50 From $6
BTIG Maintains Akoya Biosciences(AKYA.US) With Buy Rating, Maintains Target Price $6
Akoya Biosciences: Poised for Recovery and Growth Amidst Market Challenges
Akoya Biosciences to Report Second Quarter 2024 Financial Results on August 5, 2024, and Participate at Two Upcoming Investor Conferences
While Institutions Own 21% of Akoya Biosciences, Inc. (NASDAQ:AKYA), Private Equity Firms Are Its Largest Shareholders With 49% Ownership
CCORF Maintains Akoya Biosciences(AKYA.US) With Buy Rating, Maintains Target Price $6
No Data